Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
3,769
archived clinical trials in
Migraine Headaches

Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated:  4/3/2018
Meridien Research
mi
from
Brooksville, FL
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated: 4/3/2018
Meridien Research
mi
from
Brooksville, FL
Click here to add this to my saved trials
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated:  4/3/2018
MD Clinical
mi
from
Hallandale Beach, FL
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated: 4/3/2018
MD Clinical
mi
from
Hallandale Beach, FL
Click here to add this to my saved trials
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated:  4/3/2018
Suncoast Research Group, LLC
mi
from
Miami, FL
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated: 4/3/2018
Suncoast Research Group, LLC
mi
from
Miami, FL
Click here to add this to my saved trials
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated:  4/3/2018
CNS Healthcare
mi
from
Orlando, FL
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated: 4/3/2018
CNS Healthcare
mi
from
Orlando, FL
Click here to add this to my saved trials
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated:  4/3/2018
Radiant Research, Inc.
mi
from
Pinellas Park, FL
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated: 4/3/2018
Radiant Research, Inc.
mi
from
Pinellas Park, FL
Click here to add this to my saved trials
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated:  4/3/2018
Infinity Clinical Research, LLC
mi
from
Sunrise, FL
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated: 4/3/2018
Infinity Clinical Research, LLC
mi
from
Sunrise, FL
Click here to add this to my saved trials
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated:  4/3/2018
Meridien Research
mi
from
Tampa, FL
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated: 4/3/2018
Meridien Research
mi
from
Tampa, FL
Click here to add this to my saved trials
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated:  4/3/2018
Radiant Research, Inc.
mi
from
Atlanta, GA
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated: 4/3/2018
Radiant Research, Inc.
mi
from
Atlanta, GA
Click here to add this to my saved trials
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated:  4/3/2018
Urban Family Practice
mi
from
Marietta, GA
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated: 4/3/2018
Urban Family Practice
mi
from
Marietta, GA
Click here to add this to my saved trials
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated:  4/3/2018
Georgia Neurology and Sleep Medicine Associates
mi
from
Suwanee, GA
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated: 4/3/2018
Georgia Neurology and Sleep Medicine Associates
mi
from
Suwanee, GA
Click here to add this to my saved trials
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated:  4/3/2018
Northwest Clinical Trials
mi
from
Boise, ID
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated: 4/3/2018
Northwest Clinical Trials
mi
from
Boise, ID
Click here to add this to my saved trials
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated:  4/3/2018
Advanced Clinical Research, Inc.
mi
from
Meridian, ID
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated: 4/3/2018
Advanced Clinical Research, Inc.
mi
from
Meridian, ID
Click here to add this to my saved trials
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated:  4/3/2018
Michigan Avenue Internists
mi
from
Chicago, IL
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated: 4/3/2018
Michigan Avenue Internists
mi
from
Chicago, IL
Click here to add this to my saved trials
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated:  4/3/2018
Medical and Procedural Specialists of Illinois
mi
from
Chicago, IL
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated: 4/3/2018
Medical and Procedural Specialists of Illinois
mi
from
Chicago, IL
Click here to add this to my saved trials
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated:  4/3/2018
Radiant Research Inc.
mi
from
Chicago, IL
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated: 4/3/2018
Radiant Research Inc.
mi
from
Chicago, IL
Click here to add this to my saved trials
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated:  4/3/2018
Evanston Premier Research LLC
mi
from
Evanston, IL
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated: 4/3/2018
Evanston Premier Research LLC
mi
from
Evanston, IL
Click here to add this to my saved trials
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated:  4/3/2018
Clinical Research Advantage
mi
from
Evansville, IN
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated: 4/3/2018
Clinical Research Advantage
mi
from
Evansville, IN
Click here to add this to my saved trials
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated:  4/3/2018
Family Medical Associates
mi
from
Evansville, IN
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated: 4/3/2018
Family Medical Associates
mi
from
Evansville, IN
Click here to add this to my saved trials
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated:  4/3/2018
Ridge Family Practice
mi
from
Council Bluffs, IA
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated: 4/3/2018
Ridge Family Practice
mi
from
Council Bluffs, IA
Click here to add this to my saved trials
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated:  4/3/2018
Radiant Research Inc./Continuum Health Care
mi
from
Overland Park, KA
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated: 4/3/2018
Radiant Research Inc./Continuum Health Care
mi
from
Overland Park, KA
Click here to add this to my saved trials
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated:  4/3/2018
Heartland Research
mi
from
Wichita, KA
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated: 4/3/2018
Heartland Research
mi
from
Wichita, KA
Click here to add this to my saved trials
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated:  4/3/2018
Heartland Research
mi
from
Wichita, KA
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated: 4/3/2018
Heartland Research
mi
from
Wichita, KA
Click here to add this to my saved trials
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated:  4/3/2018
Boston Clinical Trials, INC.
mi
from
Boston, MA
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated: 4/3/2018
Boston Clinical Trials, INC.
mi
from
Boston, MA
Click here to add this to my saved trials
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated:  4/3/2018
Radiant Research, Inc.
mi
from
Edina, MN
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated: 4/3/2018
Radiant Research, Inc.
mi
from
Edina, MN
Click here to add this to my saved trials
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated:  4/3/2018
West Florissant Internists
mi
from
Bridgeton, MO
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated: 4/3/2018
West Florissant Internists
mi
from
Bridgeton, MO
Click here to add this to my saved trials
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated:  4/3/2018
The Center for Pharmaceutical Research, P.C.
mi
from
Kansas City, MO
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated: 4/3/2018
The Center for Pharmaceutical Research, P.C.
mi
from
Kansas City, MO
Click here to add this to my saved trials
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated:  4/3/2018
Skyline Medical Center
mi
from
Elkhorn, NE
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated: 4/3/2018
Skyline Medical Center
mi
from
Elkhorn, NE
Click here to add this to my saved trials
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated:  4/3/2018
Prairie Fields Family Medicine
mi
from
Fremont, NE
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated: 4/3/2018
Prairie Fields Family Medicine
mi
from
Fremont, NE
Click here to add this to my saved trials
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated:  4/3/2018
Southwest Family Physicians
mi
from
Omaha, NE
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated: 4/3/2018
Southwest Family Physicians
mi
from
Omaha, NE
Click here to add this to my saved trials
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated:  4/3/2018
James Mell, DO
mi
from
Henderson, NV
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated: 4/3/2018
James Mell, DO
mi
from
Henderson, NV
Click here to add this to my saved trials
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated:  4/3/2018
Clinical Research Advantage
mi
from
Henderson, NV
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated: 4/3/2018
Clinical Research Advantage
mi
from
Henderson, NV
Click here to add this to my saved trials
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated:  4/3/2018
Nevada Family Care
mi
from
Henderson, NV
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated: 4/3/2018
Nevada Family Care
mi
from
Henderson, NV
Click here to add this to my saved trials
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated:  4/3/2018
Diagnostic Center of Medicine
mi
from
Las Vegas, NV
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated: 4/3/2018
Diagnostic Center of Medicine
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated:  4/3/2018
Diagnostic Center of Medicine
mi
from
Las Vegas, NV
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated: 4/3/2018
Diagnostic Center of Medicine
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated:  4/3/2018
Clifford Molin/Clinical Research Advantage,Inc
mi
from
Las Vegas, NV
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated: 4/3/2018
Clifford Molin/Clinical Research Advantage,Inc
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated:  4/3/2018
Comprehensive Clinical Development - Queens NY
mi
from
Jamaica, NY
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated: 4/3/2018
Comprehensive Clinical Development - Queens NY
mi
from
Jamaica, NY
Click here to add this to my saved trials
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated:  4/3/2018
Radiant Research, Inc.
mi
from
Akron, OH
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated: 4/3/2018
Radiant Research, Inc.
mi
from
Akron, OH
Click here to add this to my saved trials
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated:  4/3/2018
Rapid Medical Research, Inc.
mi
from
Cleveland, OH
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated: 4/3/2018
Rapid Medical Research, Inc.
mi
from
Cleveland, OH
Click here to add this to my saved trials
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated:  4/3/2018
Radiant Research, Inc
mi
from
Columbus, OH
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated: 4/3/2018
Radiant Research, Inc
mi
from
Columbus, OH
Click here to add this to my saved trials
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated:  4/3/2018
Oklahoma City Clinic - Edmund
mi
from
Edmond, OK
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated: 4/3/2018
Oklahoma City Clinic - Edmund
mi
from
Edmond, OK
Click here to add this to my saved trials
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated:  4/3/2018
Oklahoma City Clinic - Midwest CIty
mi
from
Midwest City, OK
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated: 4/3/2018
Oklahoma City Clinic - Midwest CIty
mi
from
Midwest City, OK
Click here to add this to my saved trials
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated:  4/3/2018
LION Research
mi
from
Norman, OK
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated: 4/3/2018
LION Research
mi
from
Norman, OK
Click here to add this to my saved trials
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated:  4/3/2018
Oklahoma City Clinic- Central/Clinical Research Advantage INC
mi
from
Oklahoma City, OK
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated: 4/3/2018
Oklahoma City Clinic- Central/Clinical Research Advantage INC
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated:  4/3/2018
Lynn Health Science Institute
mi
from
Oklahoma City, OK
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated: 4/3/2018
Lynn Health Science Institute
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated:  4/3/2018
Sunstone Medical Research, LLC
mi
from
Medford, OR
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated: 4/3/2018
Sunstone Medical Research, LLC
mi
from
Medford, OR
Click here to add this to my saved trials
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated:  4/3/2018
Oregon Center for Clinical Investigations, Inc.
mi
from
Portland, OR
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated: 4/3/2018
Oregon Center for Clinical Investigations, Inc.
mi
from
Portland, OR
Click here to add this to my saved trials
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated:  4/3/2018
Thomas Jefferson University
mi
from
Philadelphia, PA
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated: 4/3/2018
Thomas Jefferson University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated:  4/3/2018
West Bay Clinical Research
mi
from
Warwick, RI
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated: 4/3/2018
West Bay Clinical Research
mi
from
Warwick, RI
Click here to add this to my saved trials
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated:  4/3/2018
Primary Care Associates, PA
mi
from
Anderson, SC
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated: 4/3/2018
Primary Care Associates, PA
mi
from
Anderson, SC
Click here to add this to my saved trials
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated:  4/3/2018
Radiant Research, Inc.
mi
from
Anderson, SC
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study
Status: Enrolling
Updated: 4/3/2018
Radiant Research, Inc.
mi
from
Anderson, SC
Click here to add this to my saved trials